Format

Send to

Choose Destination
Vaccine. 2013 Sep 13;31(40):4416-20. doi: 10.1016/j.vaccine.2013.06.080. Epub 2013 Jul 12.

Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage.

Author information

1
Centre Hospitalier Universitaire, Rouen, France; Université de Rouen, France. Valerie.delbos@chu-rouen.fr

Abstract

The aim of the study was to analyze the impact of MenBvac, an outer membrane vesicle (OMV) vaccine against P1.7,16 strains, on meningococcal carriage. During a B:14:P1.7,16/ST-32 outbreak in Normandy (France), children aged 1-7 years were randomly selected to participate in the study. Among the 1082 volunteers, there were 17 Neisseria meningitidis carriers (carriage rate of 1.57%). MenBvac vaccination appeared associated with lower carriage rate, i.e., 0.31% among the vaccinated children versus 2.10% among the non-vaccinated (p=0.03). The beneficial effect on carriage was observed regardless of the strain serogroup. OMV-vaccinated mice also showed reduction of bacterial acquisition of OMV-homolog and hererolog strains in respiratory pathways after intranasal challenge. These results suggest that meningococcal OMV-based vaccines reduce meningococcal carriage and may hence confer herd immunity.

KEYWORDS:

Carriage; Meningococci; Outbreak; Outer membrane vesicle vaccine

PMID:
23856330
DOI:
10.1016/j.vaccine.2013.06.080
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center